Ipsen scaling up in the U.S.; Samsung, Biogen submit Remicade biosimilar;

@FierceBiotech: EuroBiotech: Sanofi backs immunotherapy hub, U.K. mulls its own 'breakthrough,' Allergy player banks £20M. Report | Follow @FierceBiotech

@JohnCFierce: Coming up on 500 responses to our survey question: Sustainable bull market or biotech bubble? Let's hear from you. Survey | Follow @JohnCFierce

@DamianFierce: Science RT @NYTArchives: An unlucky kitten is volunteered to test weightlessness inside an F-94C at 25,000 feet, 1958. Picture | Follow @DamianFierce

> Ipsen is planning a major U.S. offensive, staffing up at its Cambridge, MA, hub with hopes of raising its profile in the country. News

> Partners Samsung and Biogen Idec ($BIIB) have submitted European regulatory applications for a biosimilar of Johnson & Johnson's ($JNJ) blockbuster autoimmune treatment Remicade. More

> Chinese CRO WuXi PharmaTech ($WX) is planning to build a U.S. manufacturing operation dedicated to CAR-T treatments and other cancer immunotherapies. Release

Medical Device News

@FierceMedDev: 23andMe launches new therapeutics group with biotech vet taking the reins. FierceDiagnostics story | Follow @FierceMedDev

@VarunSaxena2: Irish research center wins EU funding to study and develop transdermal delivery methods. More from FierceDrugDelivery | Follow @VarunSaxena2

@EmilyWFierce: ICYMI yesterday: FDA calls for panel meeting to discuss devices linked to superbug outbreak. Article | Follow @EmilyWFierce

> Zimmer recalls part of Persona--a total knee replacement that helped drive 2014 growth. More

> Medtronic launches U.S. clinical trial of its newest drug-eluting stent. Article

Pharma News

@FiercePharma: Mylan recalls drug after problem uncovered with Indian supplier. FiercePharmaManufacturing article | Follow @FiercePharma

@EricPFierce: DEA says it is not the cause of shortages of scheduled drugs, that it is just misunderstood. More from FiercePharmaManufacturing | Follow @EricPFierce

@CarlyHFierce: ICYMI: Glaxo to reap $890M as it halves stake in South Africa's Aspen. Story | Follow @CarlyHFierce

> Newly beefed-up Par Pharma files for an IPO. Article

> Cancer Drug Fund has failed, ex-health minister says: PMLive. Story

Suggested Articles

When thinking about clinical research patient recruitment, a crucial step is building effective patient recruitment advertising campaigns.

Novavax delayed the start of a large phase 3 trial for its COVID-19 vaccine in the U.S. and Mexico, thanks to delays in scaling up manufacturing.

The decision to dump IL33r antagonist GSK3772847 follows lackluster clinical data on rival candidates against the same target.